Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin

被引:12
作者
Vuagnat, BB [1 ]
Mach, JP [1 ]
Le Doussal, JM [1 ]
机构
[1] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
关键词
complement; alternative pathway; properdin; immunotherapy;
D O I
10.1016/S0161-5890(00)00069-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Properdin (P) is a serum glycoprotein thai stabilizes the labile C3 convertase (C3bBb) of the alternative pathway of the complement system (AP). Thanks to its oligomeric nature, P specifically upregulates AP on surfaces without activating AP in the fluid-phase. We investigated whether human cells, displaying P at their membrane, could activate autologous AP. The cDNAs encoding human P and the transmembrane domain of human platelet derived growth factor receptor were fused together and expressed in human embryo kidney cells (HEK-293). Selected cells displayed P at their surface as shown by FAGS. In contact with human serum at 37 degreesC, they triggered AP-mediated C3 deposition. SDS-PAGE analysis showed C3 covalently bound to various membrane proteins, but not to P itself. However, displayed P affinity could bind to serum or purified C3i at 4 degreesC. C3 binding was restricted to the cells displaying P, was inhibited by an anti-P mAb, and did not require serum P. Bound C3 allowed further C5, C7 and C9 deposition as well as cell lysis after blocking CD59 function. In contrast, wild-type cells, cells displaying factor D or truncated P (deleted from its 6th thrombospondin-like repeat) did not activate AP. We hypothesize that displayed P activates AP by stabilizing bystander C3b and/or by capturing serum C3iBb convertase. Finally, we suggest that P could be used for retargeting autologous complement to AP-resistant pathogens and tumor cells. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:467 / 478
页数:12
相关论文
共 49 条
[1]  
ALSENZ J, 1990, CURR TOP MICROBIOL I, V153, P243
[2]  
ARLAUD GJ, 1993, ASSEMBLY CL COMPLEX, P189
[3]   COMPUTER CALCULATION OF MULTIPLE BINDING EQUILIBRIUM ISOTHERMS - APPLICATION TO THE BINDING OF BIVALENT LIGANDS TO ANTIBODIES INTERACTING WITH CELL-SURFACE FC-RECEPTORS [J].
BARBET, J ;
LEDOUSSAL, JM ;
GRUAZGUYON, A ;
MARTIN, M ;
GAUTHEROT, E ;
DELAAGE, M .
JOURNAL OF THEORETICAL BIOLOGY, 1993, 165 (03) :321-340
[4]   COMPLEMENT COMPONENT-C3 FIXES SELECTIVELY TO THE MAJOR OUTER-MEMBRANE PROTEIN (MOMP) OF LEGIONELLA-PNEUMOPHILA AND MEDIATES PHAGOCYTOSIS OF LIPOSOME-MOMP COMPLEXES BY HUMAN MONOCYTES [J].
BELLINGERKAWAHARA, C ;
HORWITZ, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (04) :1201-1210
[5]  
BISHAYEE S, 1989, J BIOL CHEM, P1169
[6]  
DAHA MR, 1976, J IMMUNOL, V116, P1
[7]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654
[9]   ISOLATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR HUMAN C-MYC PROTO-ONCOGENE PRODUCT [J].
EVAN, GI ;
LEWIS, GK ;
RAMSAY, G ;
BISHOP, JM .
MOLECULAR AND CELLULAR BIOLOGY, 1985, 5 (12) :3610-3616
[10]   ANALYSIS OF THE INTERACTIONS BETWEEN PROPERDIN, THE 3RD COMPONENT OF COMPLEMENT (C-3), AND ITS PHYSIOLOGICAL ACTIVATION PRODUCTS [J].
FARRIES, TC ;
LACHMANN, PJ ;
HARRISON, RA .
BIOCHEMICAL JOURNAL, 1988, 252 (01) :47-54